Seed Fonds Aachen
VC Fund
Aachen, Germany
Seed Fonds Aachen is a VC fund in Aachen focused on Biotechnology and Medical. Seed Fonds has a strong competence network with national and international investors, business angels & expertes from the industry. They are specialized in the development of comprehensive financing models offering stability and development opportunities on the long term.
- Total investments:
- 8
- Last investment:
- Lead investor:
- 25%
Last updated:
For AI agents: llms.txt
Industries Seed Fonds Aachen invests in
Stages Seed Fonds Aachen invests in
Countries Seed Fonds Aachen invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
4 more contacts available
Round size
- Series A
- $2.2M–$6M
Investment Focus
Industry
- Biotechnology 4 (50%)
- Medical 2 (25%)
- Health Care 2 (25%)
- Medical Device 2 (25%)
- Mobile 1 (13%)
Stage
- Funding Round 4 (50%)
- Seed 2 (25%)
- Series A 1 (13%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Markus Krückemeier
Managing Director
|
Managing Director | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Hemovent
|
Based in Aachen, Germany, Hemovent is a privately held medical technology company that is developing a portable ECMO (Extra Corporeal Membrane Oxygenation) unit. Hemovent was founded by serial entrepreneur, Christof Lenz and Oliver Marseille, inventors of the company’s proprietary platform. It is the goal of the company to develop aninnovative solution, with precision and craftsmanship, that will aide patients with lung and heart function while allowing them to be mobile. | $2.2M / Series A / Jul 25, 2017 | |
|
Hemovent
|
Based in Aachen, Germany, Hemovent is a privately held medical technology company that is developing a portable ECMO (Extra Corporeal Membrane Oxygenation) unit. Hemovent was founded by serial entrepreneur, Christof Lenz and Oliver Marseille, inventors of the company’s proprietary platform. It is the goal of the company to develop aninnovative solution, with precision and craftsmanship, that will aide patients with lung and heart function while allowing them to be mobile. | $6M / Series A / Feb 10, 2016 | |
aquila biolabs
|
aquila biolabs is a German technology company focusing on the development of innovative laboratory devices for the analysis of shake-flask fermentations in biotechnological, chemical and pharmaceutical research and development. | Seed / Nov 10, 2015 | |
miacosa
|
miacosa.de is operated by the Endorsed Goods GmbH. miacosa.de is a social shopping concept from Germany based in Cologne. Social Shopping the miacosa way means that members select their personal shopping team of experts and celebrities that present products they love on miacosa.de Miacosa is for members only. The free service starts with productsfrom the fields of Health Style, Home & Living, Kitchen and fashion accessories. | Apr 12, 2013 | |
Augmentation Industries
|
Based on the Internet of Things and machine to machine (M2M) communication AI developed hardware and implemented an open Vehicle-2-X (V2X) interface that connects cars manufactured after 1996 to the internet and is accessible with a smartphone via WiFi. Crowd developers are able to develop own apps for the car and B2B customers are able to use theinterface to offer automotive near services (e.g. insurance, repair, reselling, gas, IRS, emergency services, etc.).Products/Services: Fully automated drivers log, fleet management, rental service, pre repair diagnostics, black box, odometer temper protection, eCall, contactless payment, etc.USP/Unique Technologies/Special Know-how: 5 pending patents lay the foundation of the IP. Beside that AI offers a solution that is capable of a complete car diagnostic and not only the OBD-II protocol as some competitors offer with a complete E2E roundtrip that no solution offers. Furthermore does the security concept and RESTful API provide a unique approach that is very positively received in presentations of the solution and its capabilities.Distribution: It is a highly scalable model as the technology is based on a global standard and therefore easily rolled out after translation of language files. The multi-tiered sales approach focuses in the first instance on direct sales to B2B (e.g. fleet management, logistics providers) in the second stage B2B2C is approached (e.g. insurance companies, automobile clubs) and in the final stage the rollout is taken to the B2C market (e.g. cheap gas pumping, CO2 challenges). | $1.6M / Seed / Sep 01, 2012 | |
Vimecon
|
Vimecon develops and produces laser catheters for the treatment of heart diseases with a focus on atrial fibrillation. It also manufactures products for the medical technology and biotechnology; and offers microscopically small catheters, as well as micro materials handling techniques for exact measurement and dosage. Moreover, Vimecon advisesvarious customers from the scholar and industrial research and development. Kai U. Markus founded it in 2005, with its headquarters in Herzogenrath in Germany. | Jun 20, 2011 | |
audimark GmbH
|
The audimark GmbH positions itself as a market-leading marketer of web radios. | Jan 21, 2010 | |
m2p-labs
|
m2p-labs was founded in November 2005 as a spin off of the department of biochemical engineering and the institute of materials in electrical engineering of the RWTH Aachen University. m2p-labs is a biotechnology company focused on the support of micro reaction solutions in biochemical engineering. The company offers a unique quantitative microreactor cultivation system which is applicable in high content screening and bioprocess development. | $658K / Aug 11, 2008 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does Seed Fonds Aachen invest in?
Seed Fonds Aachen invests primarily in Biotechnology, Medical and Health Care startups, most often at Funding Round and Seed stage. Most of the 8 investments tracked by Shizune back companies in Germany. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Seed Fonds Aachen's check size?
Seed Fonds Aachen typically joins rounds of $2.2M–$6M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Seed Fonds Aachen participates in.
How do I contact Seed Fonds Aachen?
Public channels for Seed Fonds Aachen include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Seed Fonds Aachen?
The team at Seed Fonds Aachen includes Markus Krückemeier (Managing Director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
